Poppinga Jelte, Ritter Alina S, Steinkraus Kira C, Nießen Anna, Hackert Thilo
Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Visc Med. 2025 May 15:1-7. doi: 10.1159/000546416.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with early detection and surgical resection being the only potentially curative treatment option. Despite advancements in diagnostics and surgical techniques, the prognosis of early-stage PDAC remains poor. Understanding the indications, approaches and perioperative management are crucial for improving patient survival.
Surgical resection remains the only curative treatment for early-stage PDAC. Different surgical procedures are performed depending on tumor location and local extent. Advances in minimally invasive surgery (MIS) yielded promising results regarding postoperative recovery and oncologic outcomes. The implementation of neoadjuvant therapy has improved resection and survival rates. Still, pancreatic surgery is associated with significant morbidity.
Surgical resection remains the only curative option for early-stage pancreatic cancer. Neoadjuvant chemotherapy plays a crucial role in improving resection and survival rates. Perioperative care has been refined by MIS, optimized surgical techniques, and structured complication management.
胰腺导管腺癌（PDAC）仍然是最致命的恶性肿瘤之一，早期检测和手术切除是唯一可能治愈的治疗选择。尽管诊断和手术技术取得了进展，但早期PDAC的预后仍然很差。了解适应症、手术方法和围手术期管理对于提高患者生存率至关重要。
手术切除仍然是早期PDAC的唯一治愈性治疗方法。根据肿瘤位置和局部范围进行不同的手术操作。微创手术（MIS）的进展在术后恢复和肿瘤学结果方面产生了有希望的结果。新辅助治疗的实施提高了切除率和生存率。然而，胰腺手术仍伴有显著的发病率。
手术切除仍然是早期胰腺癌的唯一治愈选择。新辅助化疗在提高切除率和生存率方面起着关键作用。围手术期护理通过MIS、优化的手术技术和结构化的并发症管理得到了改善。
